Clinical Trial Update: Sirolimus for Focal Segmental Glomerulosclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sirolimus for focal segmental glomerulosclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Focal Glomerulosclerosis | Phase 2 | Status: COMPLETED